Magnesium Threonate

Mechanism of Action

The available evidence regarding magnesium threonate's mechanism of action is extremely limited. Based on the evidence provided, there are only a few studies that offer any insight into how this compound might work at the molecular and physiological level.

Bioavailability and Delivery

One comparative preclinical study (PMID: 42084749) examined magnesium-L-threonate alongside magnesium-acetyl-taurate, investigating bioavailability, synaptic plasticity, and cognitive functions. However, this study title suggests that magnesium-acetyl-taurate showed enhanced benefits compared to magnesium-L-threonate, though the specific mechanistic details are not available from the evidence provided.

Potential Anti-inflammatory Effects

The most mechanistically relevant evidence comes from a study on cyclophosphamide-induced cystitis (PMID: 41985648), which found that magnesium-L-threonate normalization of magnesium deficiency "alleviates bladder overactivity" through "mechanisms of inflammatory modulation and barrier restoration." This suggests the compound may work by:

• Correcting magnesium deficiency
• Modulating inflammatory pathways
• Supporting tissue barrier function

However, the specific molecular pathways involved in these effects are not detailed in the available evidence.

Evidence Limitations

It's important to note that the evidence base is quite thin regarding magnesium threonate's mechanism of action. Most of the provided studies focus on unrelated compounds or applications (tea cultivars, plant biology, starch analysis, sepsis biomarkers, etc.). The clinical trials listed examine effects on sleep, recovery, athletic performance, and early Alzheimer's disease, but their mechanistic findings are not available in the evidence provided.

The proposed mechanism that magnesium threonate enhances magnesium delivery across the blood-brain barrier due to the threonate component is not directly supported by the evidence provided. More research is needed to establish the specific molecular and physiological mechanisms by which this compound exerts its effects.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical decisions.

Clinical research on magnesium threonate (specifically magnesium-L-threonate) remains limited, with only a handful of completed studies and several ongoing or planned trials examining its therapeutic potential.

Cognitive and Neurological Applications

The primary clinical focus has been on cognitive enhancement and early-stage Alzheimer's disease. Two completed Phase 2 trials (NCT03531684 and NCT03601169) investigated magnesium-L-threonate in early Alzheimer's disease patients and older adults, examining both efficacy/safety and dosage comparisons. However, specific results from these trials are not available in the current evidence base.

Preclinical research suggests magnesium-L-threonate may have neurophysiological benefits, though one comparative study (PMID: 42084749) found that magnesium-acetyl-taurate demonstrated superior bioavailability and effects on synaptic plasticity compared to magnesium-L-threonate in laboratory models.

Urological Applications

Emerging research indicates potential therapeutic value for bladder dysfunction. One study (PMID: 41985648) demonstrated that magnesium-L-threonate supplementation normalized magnesium deficiency and alleviated bladder overactivity in a cyclophosphamide-induced cystitis model, apparently through anti-inflammatory mechanisms and barrier restoration.

Athletic Performance and Recovery

Current clinical trials are investigating magnesium-L-threonate for sports medicine applications. Two active studies (NCT07015047 and NCT07640685) are examining its effects on sleep quality, recovery, and athletic performance in collegiate athletes, though results are not yet available.

Stress and Sleep Management

One completed trial (NCT06889584) evaluated a supplement combination including magnesium threonate for stress and sleep outcomes, but specific findings are not detailed in the available evidence.

Clinical Evidence Limitations: The clinical evidence base for magnesium threonate remains thin, with most trials recently completed or still ongoing. Published results from human studies are not readily available, making it difficult to draw definitive conclusions about clinical efficacy for any indication. More robust clinical data is needed to establish therapeutic applications and optimal dosing protocols.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before starting any new supplement regimen.

Evidence Limitation Disclaimer: The available evidence on magnesium threonate safety is extremely limited. The provided research includes only a few relevant studies, with most focusing on efficacy rather than comprehensive safety evaluation. The safety profile presented here should be considered preliminary.

Known Side Effects

Based on the limited available evidence, specific side effects of magnesium threonate are not well-documented in the provided research. The studies referenced do not provide detailed adverse event profiles for this compound specifically.

Evidence gap: No comprehensive safety studies or systematic adverse event reporting for magnesium threonate were found in the provided evidence.

General Magnesium-Related Considerations

While not specific to magnesium threonate, magnesium supplementation in general may be associated with gastrointestinal effects, though the threonate form's specific tolerability profile requires further investigation.

Contraindications

Evidence limitation: The provided research does not establish specific contraindications for magnesium threonate.

Drug Interactions

No evidence provided: The available studies do not investigate potential drug interactions with magnesium threonate.

Populations That Should Exercise Caution

Evidence gap: The provided research does not identify specific populations who should avoid magnesium threonate, though one study (PMID: 41985648) examined its effects in a disease model (cyclophosphamide-induced cystitis), suggesting potential therapeutic applications rather than safety concerns.

Clinical Trial Safety Data

Several clinical trials are listed (NCT03531684, NCT03601169, NCT06889584), including Phase 2 studies in early Alzheimer's disease and older adults, but specific safety outcomes from these trials are not provided in the available evidence.

---

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Individuals considering magnesium threonate supplementation should consult with a healthcare provider, particularly given the limited safety data currently available for this specific compound.

Critical Evidence Gap: The safety profile of magnesium threonate requires substantial additional research, including systematic adverse event monitoring, drug interaction studies, and identification of contraindicated populations.

Research Papers and Clinical Trials

The available research on magnesium threonate is limited, with only a small number of studies directly investigating this compound.

Preclinical Research

Two animal studies provide the primary evidence for magnesium threonate's potential effects:

A 2026 comparative preclinical study (PMID: 42084749) examined magnesium-L-threonate against magnesium-acetyl-taurate, focusing on bioavailability, synaptic plasticity, and cognitive functions. However, specific sample sizes and detailed methodology are not available from the current evidence.

Another 2026 study (PMID: 41985648) investigated magnesium-L-threonate in a cyclophosphamide-induced cystitis model, examining its effects on bladder overactivity through inflammatory modulation and barrier restoration mechanisms. Again, study design details are not provided in the available evidence.

Clinical Trials

Five clinical trials are registered to study magnesium threonate, though most lack detailed published results:

Completed Studies:

• Two Phase 2 trials examined "MMFS" (likely referring to a magnesium threonate formulation) in early Alzheimer's disease (NCT03531684) and compared different dosages in older adults (NCT03601169)
• One completed trial studied a supplement combination including magnesium threonate for stress and sleep (NCT06889584)

Ongoing/Planned Studies:

• A study examining magnesium L-threonate's effects on sleep, recovery, and athletic performance in collegiate athletes is active but not recruiting (NCT07015047)
• A UCLA study on magnesium formulation in athletes has not yet begun recruiting (NCT07640685)

Research Limitations

The current evidence base for magnesium threonate is notably thin. Most studies lack published results with detailed sample sizes, methodology, or outcome data. The majority of research appears to be in early stages, with limited peer-reviewed publications available. More robust clinical data is needed to establish the compound's efficacy and safety profile.

This information is for educational purposes only and should not be considered personalized medical advice. Consult with a healthcare provider before starting any new supplement regimen.

Protocols

Based on the limited available evidence, dosing protocols for magnesium L-threonate are not well-established in peer-reviewed literature. The evidence base is sparse, with most information coming from clinical trial registrations rather than published results.

Current Clinical Trial Approaches:

Several clinical trials have investigated magnesium L-threonate, but specific dosing details are not available from the trial registrations provided. Studies have examined its use in:

• Early Alzheimer's disease (Phase 2 trials)
• Sleep and athletic performance in collegiate athletes
• Stress and sleep supplementation combinations
• Dosage comparisons in older adults

Preclinical Findings:

One comparative study (PMID: 42084749) examined magnesium-L-threonate versus magnesium-acetyl-taurate for neurophysiological benefits, focusing on bioavailability and cognitive functions. However, specific dosing protocols from this research are not detailed in the available evidence.

Another study (PMID: 41985648) investigated magnesium-L-threonate for bladder overactivity in a cyclophosphamide-induced cystitis model, but again, specific dosing information is not provided in the available abstracts.

Evidence Limitations:

The current evidence base lacks published, peer-reviewed protocols for magnesium L-threonate dosing in humans. Most clinical trials are either ongoing, not yet recruiting, or completed without published results available in this evidence set.

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Dosing of any supplement should be determined in consultation with a qualified healthcare provider who can assess individual needs, potential interactions, and safety considerations.

Based on the available evidence, reported outcomes for magnesium L-threonate are limited to preclinical studies and a small number of clinical trials with minimal published results.

Preclinical Findings

The strongest evidence comes from animal studies examining specific mechanisms:

Bladder Function: One 2026 study reported that magnesium L-threonate normalized magnesium deficiency and alleviated bladder overactivity in a cyclophosphamide-induced cystitis model. The study identified mechanisms involving inflammatory modulation and barrier restoration, though specific quantitative outcomes were not detailed in the available evidence.

Comparative Neurophysiological Effects: A 2026 comparative study examined magnesium L-threonate against magnesium-acetyl-taurate, measuring bioavailability, synaptic plasticity, and cognitive functions in preclinical models. However, the study actually found enhanced benefits favoring the comparator (magnesium-acetyl-taurate) over magnesium L-threonate, though specific numerical outcomes are not provided in the available evidence.

Clinical Trial Evidence

The evidence base includes several completed and ongoing clinical trials, but published outcome data is extremely limited:

Alzheimer's Disease: Two Phase 2 trials (NCT03531684, NCT03601169) examining efficacy and safety in early Alzheimer's disease and dosage comparisons in older adults have been completed, but specific measurable results are not available in the provided evidence.

Athletic Performance: One active trial (NCT07015047) is examining effects on sleep, recovery, and athletic performance in collegiate athletes, but results are pending.

Sleep and Stress: A completed trial (NCT06889584) investigated supplement combinations including magnesium threonate on stress and sleep outcomes, but specific results are not reported.

Evidence Limitations

The current evidence base is notably thin. While multiple clinical trials have been conducted or are underway, published quantitative outcomes, biomarker changes, or symptom improvement data are not available in the accessible literature. Most studies appear to be recent (2026), suggesting results may not yet be fully published or peer-reviewed.

Disclaimer: This summary is for informational purposes only and does not constitute medical advice. Consult healthcare providers for personalized recommendations regarding magnesium supplementation.